Home > Research > Publications & Outputs > Deconstructing Schizophrenia

Links

Text available via DOI:

View graph of relations

Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification

Research output: Contribution in Book/Report/Proceedings - With ISBN/ISSNChapter (peer-reviewed)peer-review

Published

Standard

Deconstructing Schizophrenia : Advances in Preclinical Models for Biomarker Identification. / Pratt, Judith A; Morris, Brian; Dawson, Neil.

Current Topics in Behavioral Neurosciences. Berlin : Springer, 2019. p. 295-323.

Research output: Contribution in Book/Report/Proceedings - With ISBN/ISSNChapter (peer-reviewed)peer-review

Harvard

Pratt, JA, Morris, B & Dawson, N 2019, Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification. in Current Topics in Behavioral Neurosciences. Springer, Berlin, pp. 295-323. https://doi.org/10.1007/7854_2018_48

APA

Pratt, J. A., Morris, B., & Dawson, N. (2019). Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification. In Current Topics in Behavioral Neurosciences (pp. 295-323). Springer. https://doi.org/10.1007/7854_2018_48

Vancouver

Pratt JA, Morris B, Dawson N. Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification. In Current Topics in Behavioral Neurosciences. Berlin: Springer. 2019. p. 295-323 https://doi.org/10.1007/7854_2018_48

Author

Pratt, Judith A ; Morris, Brian ; Dawson, Neil. / Deconstructing Schizophrenia : Advances in Preclinical Models for Biomarker Identification. Current Topics in Behavioral Neurosciences. Berlin : Springer, 2019. pp. 295-323

Bibtex

@inbook{07d649dbadc846538e5ee56bd6ea8f59,
title = "Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification",
abstract = "Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia. Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).",
keywords = "Journal Article",
author = "Pratt, {Judith A} and Brian Morris and Neil Dawson",
year = "2019",
month = feb,
day = "28",
doi = "10.1007/7854_2018_48",
language = "English",
isbn = "9783319996417",
pages = "295--323",
booktitle = "Current Topics in Behavioral Neurosciences",
publisher = "Springer",

}

RIS

TY - CHAP

T1 - Deconstructing Schizophrenia

T2 - Advances in Preclinical Models for Biomarker Identification

AU - Pratt, Judith A

AU - Morris, Brian

AU - Dawson, Neil

PY - 2019/2/28

Y1 - 2019/2/28

N2 - Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia. Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).

AB - Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia. Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).

KW - Journal Article

U2 - 10.1007/7854_2018_48

DO - 10.1007/7854_2018_48

M3 - Chapter (peer-reviewed)

C2 - 29721851

SN - 9783319996417

SP - 295

EP - 323

BT - Current Topics in Behavioral Neurosciences

PB - Springer

CY - Berlin

ER -